Topline data were announced from two phase 3 trials evaluating amlitelimab for the treatment of moderate to severe atopic dermatitis.

Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Jan. /CNW/ — USA News Group News Commentary – Global capital is officially rotating into “Longevity Infrastructure” which is ...

Group results In 2025, Roche achieved sales growth of 7% (2% in CHF) to CHF 61.5 billion due to strong demand for pharmaceutical products and diagnostic solutions. The appreciation of the Swiss franc ...

Many claim the latest viral ingredient is as good as filler. Experts weigh in on the truth (and now to use the product in ...

Group sales grew by 7%1 at constant exchange rates (CER; 2% in CHF), driven by strong demand for medicines and diagnostic solutions.Sales in the fourth quarter increased by 8%, reflecting the positive ...